If you’ve been wanting to try psychedelic therapy legally, now’s your chance!
Johns Hopkins is recruiting participants for a number of psilocybin studies on:
Plus, Nova Mentis is recruiting both autisitc and neurotypical patients for an observational study that will lead to a psilocybin microdosing study.
If you want to contribute to psychedelic research from home, check out Johns Hopkins’ online surveys on psychedelics and breathwork for anxiety, depression, and PTSD.
New studies suggest that COMPASS Pathways’ proprietary psilocybin has promise in treating some of the most challenging mental health conditions: severe treatment-resistant depression and anorexia nervosa.
After a single dose of psilocybin, 58.3% of patients with severe treatment-resistant depression (meaning they’d tried 5+ antidepressant treatments without success) had a reduction in depression scores for 12 weeks.
One quarter of patients no longer qualified for a depression diagnosis.
In the anorexia study, 30% of patients had significant reductions in symptoms at the 1-month follow up, increasing to 40% at the 3-month follow up.
Patients with PTSD often have eating disorders too. MDMA is known to improve self acceptance and emotional processing, so it may be the perfect treatment for both!
In MAPS’ Phase 3 trial on MDMA for PTSD, 42%* of patients scored in the “clinical” or “at-risk” range on an eating disorder scale prior to the treatment.
MDMA therapy was found to significantly reduce eating disorder symptoms in comparison to a placebo.
MAPS is commencing a multi-site Phase 2 trial this May to further examine MDMA therapy on both anorexia and binge eating.
*Patients with active purging were excluded as a precaution to avoid cardiac arrhythmias.
Anorexia has a higher mortality rate than any other psychiatric condition, as patients have a high risk of death by both suicide and organ failure.
Current treatments work for less than half of patients, which is why Imperial College London is preparing to study psilocybin therapy as an alternative.
The school is recruiting female patients who have had a diagnosis for at least 3 years and have tried other forms of treatment without success. They’ll each receive 3 doses of psilocybin, and researchers will use several MRIs and EEG scans to understand the effects of the treatment.
University of Sydney researchers received $3M in funding from the Australian government to support MDMA and psilocybin studies! The MDMA study will investigate combined PTSD and alcohol use disorder, and the psilocybin study will be focused on anorexia nervosa.
